NICE guidance - boceprevir for the treatment of genotype 1 chronic hepatitis C
Last reviewed 01/2018
Boceprevir in combination with peginterferon alfa and ribavirin is recommended as an option for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease:
- who are previously untreated or in whom previous treatment has failed
Notes:
- Boceprevir is a NS3/4A serine protease inhibitor that is administered orally
- NS3/ 4A serine protease is essential for viral replication and may be partially responsible for the ability of the hepatitis C virus (HCV) to evade clearance by the host immune system
- Boceprevir has a UK marketing authorisation 'for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy'
Reference: